Compounded vs. Brand GLP-1, on a Family Budget

Two prices for what looks like the same thing

Open two telehealth tabs and you will see the same active ingredient quoted at wildly different prices: brand-name Wegovy or Zepbound on one, a compounded semaglutide or tirzepatide vial at a fraction of it on the other. For a family doing the arithmetic, the gap is impossible to ignore.

But the arithmetic has moved underneath this question twice in the last eighteen months, and both moves went the same way. The compounded lane got legally narrower. The brand lane got cheaper. If you last priced this in 2024 — or read a guide written from 2024 numbers — the comparison you are carrying around is out of date.

A compounded vial is not a knockoff. It is a real product whose low price rode on a regulatory situation that has since closed.

What the trial data actually measured

Start with the fact that helps and complicates at once: the celebrated efficacy numbers belong to the brand molecules. When you read that semaglutide produced roughly 15% mean weight loss in STEP 1¹, or that tirzepatide reached near 20% in SURMOUNT-1², those trials studied the FDA-approved branded drugs at defined doses. Compounded versions use the same active ingredient, but they were not the specific products tested, and they are not FDA-approved. The FDA states the consequence plainly: "Compounded drugs are not FDA-approved. This means the agency does not review their safety, effectiveness or quality before they are marketed. Compounded drugs are also not the same as generic drugs, which are FDA-approved."⁵

It is reasonable to expect a similar effect from the same molecule at the same dose. But "reasonable to expect" is doing real work in that sentence, and an honest budget accounts for it.

Why compounded exists — and why that era has already ended

Compounded GLP-1 medicines expanded because the brand products spent long stretches on the FDA's drug-shortage list, and federal rules give compounders latitude when a drug is in shortage. That is the legitimate origin story, and it is now history rather than a live condition.

FDA's own compounder guidance states that "Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list", and that for state-licensed pharmacies compounding semaglutide injection under section 503A, "the period of enforcement discretion ... has ended"³. The agency has kept moving since. In February 2026 it announced its intent "to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed" — naming companies including Hims & Hers, and warning that failure to address violations "may result in legal action without further notice, including, without limitation, seizure and injunction"⁴. In March 2026 it issued 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1 products, a second round after an earlier batch⁵.

This is the part the old advice gets wrong. The risk is not that the rules might tighten one day. They tightened. What you are shopping in now is the aftermath.

What is actually on the shelf now

So what survived? Mostly, personalization — and researchers have gone and looked at it rather than guessing.

In a cross-sectional secret-shopper study published in JAMA Health Forum in 2026, investigators contacted 75 brick-and-mortar weight-loss clinics and medical spas in two states with high likely demand, West Virginia and Oklahoma, between August and October 2025. Of those businesses, 42 (56.0%) offered a compounded GLP-1 combined with B vitamins. Of the 23 supplying compounding facilities they identified, 4 of 21 (19.0%) were not licensed to perform sterile compounding, and 3 of 22 (13.6%) had been subject to state-level disciplinary action⁶.

Hold that 56% next to what FDA wrote. The agency specifically says it may treat a product combining "semaglutide API and another API, such as vitamin B12 (cyanocobalamin)" as essentially a copy of a commercially available drug when the route and strengths line up³. In other words, the most common thing the post-shortage market is selling is the exact configuration the regulator named. That does not make every B-vitamin blend unlawful — a prescriber can document a significant difference for an individual patient — but it does mean a family buying one is standing much closer to the enforcement line than the checkout page suggests.

The nineteen percent is the number that should actually move you, though. A vial you inject weekly, from a facility not licensed to compound sterile products, is not a pricing question. It is a safety question.

Three real listings from an August 2026 check of what's actually for sale, so this isn't abstract: MangoRx sells a compounded oral semaglutide-and-B6 tablet at a flat $299/mo — no B12, but the same personalization logic the FDA is watching. Pomegranate Health advertises injectable compounded semaglutide from $119/mo and has quietly dropped tirzepatide from its catalog since an earlier check. Ivologist prices its 11-week compounded semaglutide program two different ways across two of its own pages — a weekly figure on the homepage, a monthly figure on the product page — worth reading closely rather than assuming they match.

Four more, all compounded: Care Clinics at $100/$133/mo, cheapest here, no pharmacy named. Elara Health and Wellness at $183/$268/mo, bundling labs and coaching in. Spry at $199/$299/mo. Aurelius Health Group is a different shape — only a low-dose "microdosed" tirzepatide protocol, $89 then $199/mo, no semaglutide.

What people wrote down while they were choosing

None of this is how the decision feels from inside a kitchen at eleven at night.

In a published thematic analysis of 660 posts on r/WegovyWeightLoss, researchers found "barriers to access" accounted for 10.7% of coded posts — the fourth-largest of seven themes⁷. The quoted posts are not dramatic. One reads, in full: "Paying out of pocket for Wegovy is unsustainable." Another describes the improvised route people took when supply and price both failed them: "I went to my primary care doctor yesterday. I had sent her multiple messages through the portal they have about my troubles finding a prescription for 0.5 mg. I asked she send it to Amazon, and got no response. She is referring me to a weight management place where they can give me compounds."

Read that second one carefully. Nobody in it chose compounded on the merits. She chose it because the brand version was not there, and the referral was the door that opened. That is how most people arrived in this lane — and it is why the lane closing matters more than a price comparison suggests.

The brand lane got cheaper while you were not looking

Meanwhile the other side of the comparison moved. Novo Nordisk's self-pay terms put Wegovy at "$199 for each month of 0.25 mg & 0.5 mg" for two monthly fills, then "$349 per month" for the standard pen doses; the Wegovy pill runs "$149 for each month of 1.5 mg and 4 mg", with the 4 mg offer stated as running only until August 31, 2026⁸. Eli Lilly quotes Zepbound self-pay at "as low as $299" for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg and above, with the top rate conditional on refilling within 45 days⁹.

Those are FDA-approved products, at prices that sit in the same band compounded vials were advertised in — sometimes below. The discount that justified the trade-off is not reliably there any more. (All of these carry expiry dates and change often; price both lanes yourself on the day you decide.)

Doing the honest math for your family

So how should a mother weigh it now? Price the maintenance dose, not the starting dose, because that is where you will live — the same logic that governs the true cost of a GLP-1 over time. Price the brand lane before you assume it is out of reach, including through insurance, which can make a "more expensive" brand cheaper than a "cheap" vial once coverage applies. If you are quoted a compounded product, ask which pharmacy makes it, whether that pharmacy is licensed for sterile compounding, and what exactly is in it besides the GLP-1 — and take those answers to a clinician who knows your history before you inject anything.

If the brand lane is where you land, the thing actually worth paying for is not the prescription — it is somebody to fight your insurer for it, and almost nobody sells that separately. WeightWatchers Clinic is the clearest example on our board: brand pens only, no compounded option at all, and a membership whose stated job includes an insurance coordinator who "will make the calls" and manages the prior authorizations. It publishes that membership price to the dollar and no medication price whatsoever, which tells you precisely where the uncertainty in this lane sits. Ro runs the same shape with a dedicated insurance concierge and six brand-name options, and LifeMD — a name that used to circulate as a cheap compounded pick — has moved the same direction, its own site now steering patients toward the FDA-approved lane now that the shortage exemption it relied on has closed.

There is no universally right answer here. There is only the one that survives your budget with your eyes open, and the honest news of 2026 is that the eyes-open answer is no longer automatically the cheap-looking one.